Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma
Author:
Affiliation:
1. Department of Medical Oncology, Istituto Nazionale dei Tumori, Milan, Italy
2. Department of Medical Oncology, Unit 1 Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milan, Italy
Abstract
Publisher
SAGE Publications
Subject
Urology
Link
http://journals.sagepub.com/doi/pdf/10.1177/1756287215574457
Reference35 articles.
1. Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma
2. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
3. Prognostic Factors in Patients with Advanced Renal Cell Carcinoma
4. Comparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma
5. Renal-Cell Carcinoma
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with PTEN mutation: a case report and literature review;Frontiers in Endocrinology;2024-01-31
2. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease;Signal Transduction and Targeted Therapy;2023-10-02
3. ENO2 as a Biomarker Regulating Energy Metabolism to Promote Tumor Progression in Clear Cell Renal Cell Carcinoma;Biomedicines;2023-09-09
4. High-Throughput Screening of the Repurposing Hub Library to Identify Drugs with Novel Inhibitory Activity against Candida albicans and Candida auris Biofilms;Journal of Fungi;2023-08-27
5. Non-Clear Cell Renal Cell Carcinoma: Molecular Pathogenesis, Innovative Modeling, and Targeted Therapeutic Approaches;International Journal of Translational Medicine;2022-11-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3